Ingenol Mebutate (PEP005, Ingenol 3-angelate)

Chemical Structure : Ingenol Mebutate

CAS No.: 75567-37-2

Catalog No.: PC-27614Not For Human Use, Lab Use Only.

Ingenol Mebutate (PEP005, Ingenol 3-angelate) is a selective small-molecule activator of protein kinase C (PKC) with Ki of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively.

Packing	Price	Stock
5 mg	$198	In stock
10 mg	$328	In stock
25 mg	$528	In stock
50 mg		Get quote
100 mg		Get quote

Get Quotation Now

* Please select Quantity before adding items.

or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Biological Activity

Ingenol Mebutate (PEP005, Ingenol 3-angelate) is a selective small-molecule activator of protein kinase C (PKC) with Ki of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively.
Ingenol Mebutate (PEP005, Ingenol 3-angelate) induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells.
Ingenol Mebutate (PEP005, Ingenol 3-angelate) has potent antileukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary acute myeloid leukemia (AML) cells at nanomolar concentrations.
Ingenol Mebutate (PEP005, Ingenol 3-angelate) modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Physicochemical Properties

M.Wt	430.54
Formula	C25H34O6
Appearance	Solid
CAS No.
Storage	Solide Powder -20°C 12 Months; 4°C 6 Months	In Solvent -80°C 6 Months; -20°C 6 Months
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	(Z)-(1aR,2S,5R,5aS,6S,8aS,9R,10aR)-5,5a-Dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulen-6-yl 2-methylbut-2-enoate

References

1. Hampson P, et al. Blood. 2005 Aug 15;106(4):1362-8.

2. Sumarni U, et al. Cells. 2021 Apr 23;10(5):987.

3. Jiang G, et al. JCI Insight. 2019 Apr 4;4(7):e126027.

4. Freiberger SN, et al. Mol Cancer Ther. 2015 Sep;14(9):2132-42.